M. Rösner

发表

The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.

A. D. Clark, Jianping Ding, P. Boyer, 2001, Journal of molecular biology.

Biological effects of modified colchicines. Improved preparation of 2-demethylcolchicine, 3-demethylcolchicine, and (+)-colchicine and reassignment of the position of the double bond in dehydro-7-deacetamidocolchicines.

A. Brossi, R. Sik, C. Chignell, 1981, Journal of medicinal chemistry.

A substituted thieno[3.4-d]imidazole versus substituted benzimidazoles as H+, K+-ATPase inhibitors.

A. Herling, H. Lang, M. Rösner, 1988, Pharmacology.

Partial Enantiomerization of an Atropisomeric Butadiene

M. Rösner, G. Köbrich, 1974 .

Revision of the Structure of ‘Epoxycolchicine’

A. Brossi, M. Rösner, C. D. Hufford, 1980 .

Preclinical evaluation of HBY 097, a new nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 replication

R. Kaiser, M. Wichers, R. Kirsch, 1995, Antimicrobial agents and chemotherapy.

Selective pressure of a quinoxaline nonnucleoside inhibitor of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) on HIV-1 replication results in the emergence of nucleoside RT-inhibitor-specific (RT Leu-74-->Val or Ile and Val-75-->Leu or Ile) HIV-1 mutants.

E. Arnold, R. Kirsch, Y. Hsiou, 1996, Proceedings of the National Academy of Sciences of the United States of America.

Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication

Christoph, J. Kleim, R. Bender, 1993, Antimicrobial Agents and Chemotherapy.

Enantiomerization of Optically Stable Substituted Butadienes

M. Rösner, G. Köbrich, 1975 .

Reaktionen an Indolderivaten, XXXVIII. Dreiringreaktionen in der Indolreihe

M. Rösner, E. Winterfeldt, U. Rosentreter, 1979 .

Synthesis of 3'-(1,2,3-triazol-1-yl)-3'-deoxythimidines

M. Rösner, W. Barth, D. Häbich, 1989 .

In vitro selection for different mutational patterns in the HIV-1 reverse transcriptase using high and low selective pressure of the nonnucleoside reverse transcriptase inhibitor HBY 097.

R. Kirsch, J. Kleim, A. Paessens, 1997, Virology.

Antiviral activity and pharmacokinetics of HOE 602, an acyclic nucleoside, in animal models.

M. Rösner, I. Winkler, M. Helsberg, 1990, Antiviral research.

New prodrugs of acyclic nucleosides with antiviral activity.

M. Rösner, I. Winkler, G. Jähne, 1988, Arzneimittel-Forschung.

2-((2-Pyridylmethyl)sulfinyl)benzimidazoles: acid sensitive suicide inhibitors of the proton transport system in the parietal cell.

A. Herling, H. Lang, M. Rösner, 1985, Biochemical and biophysical research communications.

Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance.

A. D. Clark, Jianping Ding, S. Hughes, 1998, Journal of molecular biology.